| |
|
|
|
EuroSciCon, Cineworld: The O2 Peninsula Square London London SE10 0DX United Kingdom
Tuesday, 17 June 2014 09:30 - Thursday, 19 June 2014 17:00
This three day event will discuss three main topics
- Cell Culture Technology Event: Recent advances, future prospect
- Therapeutic proteins and antibodies: from design to function
- Bioprocess development: Discussing facilitation of industrial uptake
With plenty of opportunity for networking and debate, this informal international meeting will bring you up to date with current research and thinking.
This event has CPD accreditation Who Should Attend
All academic and biotechnology/biopharma professionals interested in biological protein and antibody engineering, functional and potency evaluations, biological therapeutics mechanisms of action and translational implications for therapy would find this meeting useful. Individuals interested in the any process that uses complete living cells or their components (e.g., bacteria, enzymes, chloroplasts) to obtain desired products should also attend this event.
The deadline for abstract submissions for oral presentation is April 10th 2014.Abstracts for poster presentation only can be submitted up to two weeks before the event.
You can download the instructions for authors at www.euroscicon.com/ABSTRACTSUBMISSIONS.pdf There will be an open poster session, where posters can be submitted on any subject related to Cells, Proteins and Bioprocessing
Program Outline
Day 1: Cell Culture Technology Event: Recent advances, future prospect
Cell culture has matured to become the pivotal technology in biopharmaceutical research, development and production, and its use in this and other areas continues to expand rapidly. In vitro models are replacing animals in many tests and assays; its enormous potential in the fields of stem cell and regenerative medicine has hardly started to be realized; its utility in research grows ever faster.
This session will examine some of the latest applications of cell culture technology, some that are still “over the horizon”, and some of the problems that must be solved before it can reach its full potential.
Day 2: Therapeutic proteins and antibodies: from design to function
This session discusses new developments in therapeutic protein and antibody engineering with specific focus on science and technology of modifying proteins and antibodies (and the conditions of their manufacture) toward specific predefined properties that allow them to act as effective biological drugs. Special emphasis will be placed on structure-function relationships, mechanisms of action, potency and efficacy in disease-relevant models and in clinical trials. There will be plenty of opportunity for discussion and debate addressing the wide range of disciplines applied to the rapid and economical production of these molecules for biological therapies
Day 3: Bioprocess development: Discussing facilitation of industrial uptake.
This will focus on recent technologies used in high throughput bioprocess development, from clone selection through to analysis of final product and formulation. Bioprocess miniaturization, effective upscaling, downstream processing and analytics will all be discussed. Expert speakers will describe the development and use of current technologies together with the technical and regulatory hurdles that must be overcome to facilitate wider industrial uptake.
Keywords: Gene correction/modification, AAV vectors, Cell line engineering, biopharmaceutical manufacturing processes, antibody purification, process economics, genetic algorithms, multi-product facility design, homologous recombination, cell line engineering, CHO cell lines, gene targeting, endogenous genome, Cell line development, cell line selection, screening, CHO, mammalian expression systems, glycosylation, protein therapeutics, E.coli, microbial, antibody, NTA, Protein Aggregation, Nanoscale, Analysis,Growth Hormone, Long Acting Biological, Fusion, Protein,protein linking, stapling, botulinum, domain, therapeutic, Affinity chromatography, Antibody purification, Therapeutic antibodies, Downtream processing,mAbs, therapeutic protein production, downstream processing, monoclonal antibodies, hormones, new technologies, Polishing, Virus, Contaminant, Cost, Time,Immunogenicity, deimmunizaion, tolerization, validtaion, immunomodulation, ADCC, therapeutic antibody, screening, quality control, therapeutic proteins, therapeutic antibodies; protein engineering; structure; functional assays, Monoclonal antibodies, Cancer therapeutics, Isotype, Fc receptors, CD40, monoclonal antibodies, cancer markers, quantum-dot, cancer imaging, cancer treatment, Monoclonal antibodies, Cancer therapeutics, Isotype, Fc receptors,cell, transfection, lasers, microscopy, Autophagy, Puncta, p62, Flux, cell, transfection, lasers, microscopy, mammalian cell culture media, batch to batch consistency, human embryonic stem cells, clinical grade, cGMP, bioreactor, process development, large scale, upstream processes, recombinant protein production; cold-shock; CHO cells; cell engineering, cell therapy,Influenza, organ culture, respiratory tract,Soluble proteins, vaccines,
cGMP,, Red blood cells, human embryonic stem cells, scale-up, DNA methylation, genomic imprinting, pluripotency, Cell Line Selection, Media Development, cell, apoptosis, multiplexing, pathways, 3D culture, Online Monitoring, 3 Dimensional Cell Culture, Scaffold, Cell based assay, additive manufacturing, electrospinning, stem cells, screening, 3D culture, Nanoparticles, Inflammation, in vitro system, Coculture, Air-liquid-interface (ALI), label-free, microscopy, stem cells,bioreactor, micro, automated, culture, single use, Microbioreactors, Well Plate, Liquid Feed, bioprocesses,fermentation, cell culture, miniature bioreactor, Antibiotics, Bio-microreactors, Bio-Process Intensification, Enzymes,Fermentation, lyophilisation, biopharmaceuticals, Freeze drying, mechanics, formulation, High through put, scalability, automation, single use, bioreactors, small scale, bioreactor, miniaturization,scale down model, parallel bioprocesses, screening, downscaling, micro fermentation, micro bioreactor, microwell, bioprocessing, biocatalysts, refolding, inclusion bodies, Purification, downstream processing, primary separation, primary capture, chromatography, filtration,polishing,Single use Technologies, purification, biopharmaceutical, nanofibres; productivity, Membrane Adsorbers, Scale Up, Biosimilars, Process Development, protein secretion, Bacillus, proteases, translocase,chaperone, biopharmaceuticals, membrane technology, precipitation, antibody purification, customization, copolymer,bioseparations, liquidliquid extraction, Mab, ATPS, Downstream Processing, Biomolecular Analysis
|
|
|
|
|
|
|
|
Organized by:
|
|
Euroscicon |
|
|
Invited Speakers:
|
|
Talks Include:
Micro-cariers: its role in reducing the cost, time, and efforts towards industrial cells proliferation and protein productions
Dr Ali Hilal-Alnaqbi, Assistant Professor UAEU, Visiting Assistant Professor, Harvard, USA
Therapeutic IgE antibodies: enhanced effector functions for cancer therapy Dr Sophia Karagiannis , Senior Research Fellow in Translational Cancer Immunology, Head of Cancer Antibody Discovery and Immunotherapy, King's College London School of Medicine, UK
Introducing a Novel liquid 3 Dimensional Scaffold for Culturing Cells in 3D
Dr Anthony Mitchell Davies, Director of INCHSA, Dept Clinical Medicine Trinity College Dublin, Ireland
Quantum dot- conjugated antibodies as diagnostic and therapeutic tools for cancer imaging and treatment
Dr Weiming Xu, CEO, London Biotech Ltd, UK
Real time, label-free characterisation of live cells in monolayer culture using high resolution, multi-modal light microscopy
Dr Melissa Mather, Principal Research Fellow, Institute of Biophysics, Imaging and Optical Science, University of Nottingham, UK
Biofabrication technologies for 3D cell culture systems
Dr Lorenzo Moroni, Associate Professor, University of Twente, Tissue Regeneration Department, The Netherlands
election of isotype for immunomodulatory anti-cancer antibodies Dr Ann White, Senior Research Fellow, University of Southampton, UK
Developing of long acting glycoprotein hormones using gene fusion and gene transfer: from bench to clinics
Professor. Fuad Fares, University of Haifa, Israel
3D-tetraculture system mimicking the cellular organization at the alveolar barrier.
Dr Arno C. Gutleb, Chef de projet, Centre de Recherche Public - Gabriel Lippmann, Luxembourg
Protein based nano and micro particles for biological applications
Dr Deepak Kalaskar UCL , London
Additional Speakers Include- Dr Sergio A. Quezada, Immune Regulation and Tumour Immunotherapy Group, UCL Cancer Institute, UK
- Dr Miriam Dwek, University of Westminster, UK
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
April 10th 2014
|
|
|
|
|
|
|
|
Registration:
|
|
Click here to register
|
|
|
E-mail:
|
|
enquiries@euroscicon.com
|
|
|
|
|
|
|
|
|